Compare BENF & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BENF | ATNM |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2M | 31.4M |
| IPO Year | 2023 | 2013 |
| Metric | BENF | ATNM |
|---|---|---|
| Price | $1.05 | $1.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.60 |
| AVG Volume (30 Days) | ★ 9.4M | 102.2K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | N/A | $19,344.45 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.49 |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.50 | $0.74 |
| 52 Week High | $60.00 | $1.74 |
| Indicator | BENF | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 45.39 | 51.40 |
| Support Level | $0.50 | $0.96 |
| Resistance Level | $3.81 | $1.13 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 31.00 | 58.62 |
Beneficient is a technology-enabled financial services holding company providing liquidity solutions and trust products and services to participants in the alternative assets industry through an online platform, AltAccess. Its services are focused on alternative asset investors, institutional investors, family offices, and fund managers. The company provides liquidity solutions for alternative asset investments through financing and trust structures. The company has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts. The majority of revenue is derived from the Ben Liquidity segment in the form of interest income.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.